Breaking News Instant updates and real-time market news.

2022-05-05 06:45:04 DEN Denbury $70.24 / +3.77 (+5.67%) 06:45 05/05/22 05/05 06:45 05/05/22 06:45	Denbury reports Q1 adjusted EPS $1.69, consensus $1.53 Reports Q1 revenue $412M, consensus $340.97M. Average daily sales volumes were 46,925 BOE/d. Oil represented 97% of the company's Q1 volumes, and approximately 25% of the company's oil was attributable to the injection of industrial-sourced CO2 in its EOR operations, resulting in carbon-negative or blue oil. CEO Chris Kendall commented, "Denbury made strong progress on our key 2022 objectives during Q1, with CO2 injection ahead of plan at the Cedar Creek Anticline EOR project and continued advancements in support of our CCUS business. The CCA EOR development, which will produce carbon-negative blue oil through 100% utilization of industrial-sourced CO2, provides the company with a deep inventory of resource development opportunities and decades of significant cash flow. I am extremely excited about our successes in the Carbon Solutions business so far this year, and I believe we are on track to substantially exceed our goals for CO2 offtake and storage agreements established at the beginning of the year. I am also pleased that Denbury's Board of Directors has authorized a $250M share repurchase program. At current oil price levels, we believe that our cash flow generation will be more than sufficient to meet our anticipated capital needs, providing the opportunity to return meaningful capital to shareholders in this manner."	05 May 01 Jun

2022-05-05 06:45:04

DEN

Denbury

$70.24 / +3.77 (+5.67%)

06:45

05/05/22

05/05

06:45

05/05/22

06:45

Denbury reports Q1 adjusted EPS $1.69, consensus $1.53

Reports Q1 revenue $412M, consensus $340.97M. Average daily sales volumes were 46,925 BOE/d. Oil represented 97% of the company's Q1 volumes, and approximately 25% of the company's oil was attributable to the injection of industrial-sourced CO2 in its EOR operations, resulting in carbon-negative or blue oil. CEO Chris Kendall commented, "Denbury made strong progress on our key 2022 objectives during Q1, with CO2 injection ahead of plan at the Cedar Creek Anticline EOR project and continued advancements in support of our CCUS business. The CCA EOR development, which will produce carbon-negative blue oil through 100% utilization of industrial-sourced CO2, provides the company with a deep inventory of resource development opportunities and decades of significant cash flow. I am extremely excited about our successes in the Carbon Solutions business so far this year, and I believe we are on track to substantially exceed our goals for CO2 offtake and storage agreements established at the beginning of the year. I am also pleased that Denbury's Board of Directors has authorized a $250M share repurchase program. At current oil price levels, we believe that our cash flow generation will be more than sufficient to meet our anticipated capital needs, providing the opportunity to return meaningful capital to shareholders in this manner."

05
May
01
Jun

OTHER BREAKING NEWS FROM THE FLY

Periodicals	Twitter loses another senior executive in charge of content, safety, WSJ says » 17:46 06/03/23 06/03 17:46 06/03/23 17:46 TWTR Twitter $53.71 / + (+0.00%) A second senior executive… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:46 Get Free Trial ShowHide Related Items >><< Company News Street Research Periodicals On The Fly TWTR Twitter $53.71 / + (+0.00%) 05/25/23 Ford, Tesla CEOs to host Twitter Spaces chat on accelerating EV adoption 05/18/23 Twitter now lets Blue subscribers upload two-hour videos 05/18/23 Supreme Court declines to address Section 230 shield in Google ruling 05/12/23 Musk says 'bringing on Linda allows me to devote more time to Tesla' TWTR Twitter $53.71 / + (+0.00%) 05/12/23 Wedbush New Twitter CEO positive for Tesla shares, says Wedbush 02/03/23 Morgan Stanley Sprout, Sprinklr pacts minimize impact of Twitter decision, says Morgan Stanley 12/19/22 Wedbush End of Twitter CEO reign would be 'major positive' for Tesla, says Wedbush 11/23/22 Morgan Stanley Morgan Stanley wonders if 'value opportunity emerging' in Tesla after selloff TWTR Twitter $53.71 / + (+0.00%) 05/23/23 DeSantis will launch his presidential bid with Elon Musk, NBC News reports 05/19/23 Meta readying Instagram text-based app to compete with Twitter, Bloomberg says 05/19/23 Meta readying Instagram text-based app to compete with Twitter, Bloomberg says 05/19/23 Meta preparing Twitter competitor for release this summer, Bloomberg says TWTR Twitter $53.71 / + (+0.00%) 05/24/23 #SocialStocks: Meta fined EUR 1.2B in Ireland for infringing on data laws 05/19/23 What You Missed On Wall Street On Friday 05/19/23 What You Missed On Wall Street This Morning 05/17/23 #SocialStocks: Tech companies seek employees abroad after hiring freeze
Hot Stocks	Janssen Pharmaceuticals announces updated data from Phase 2 TRiMM-2 study » 17:39 06/03/23 06/03 17:39 06/03/23 17:39 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) The Janssen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/03/23 Janssen presents analysis of infections, parameters in Monumen-TAL1 study 06/03/23 Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study 06/03/23 Janssen announces results from Phase 1b RedirecTT-1 study 05/31/23 Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/30/23 RBC Capital Kenvue initiated with an Outperform at RBC Capital 05/30/23 Citi Johnson & Johnson resumed with a Buy at Citi 05/30/23 JPMorgan JPMorgan starts Kenvue with Overweight on 'resilient growth' 05/30/23 Goldman Sachs Kenvue initiated with a Neutral at Goldman Sachs JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65 04/18/23 Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51 04/17/23 Notable companies reporting before tomorrow's open 02/28/23 Fate Therapeutics reports Q4 EPS (58c), consensus (86c) JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/10/23 New suitors showing interest in ShockWave Medical, Street Insider says 05/03/23 Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/02/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/30/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Unusually active option classes on open April 18th 04/06/23 Unusually active option classes on open April 6th 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th
Hot Stocks	Janssen presents analysis of infections, parameters in Monumen-TAL1 study » 17:39 06/03/23 06/03 17:39 06/03/23 17:39 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) The Janssen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/03/23 Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study 06/03/23 Janssen announces results from Phase 1b RedirecTT-1 study 05/31/23 Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis 05/25/23 Legend: Type II variation application submitted to EMA for CARVYKTI JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/30/23 RBC Capital Kenvue initiated with an Outperform at RBC Capital 05/30/23 Citi Johnson & Johnson resumed with a Buy at Citi 05/30/23 JPMorgan JPMorgan starts Kenvue with Overweight on 'resilient growth' 05/30/23 Goldman Sachs Kenvue initiated with a Neutral at Goldman Sachs JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65 04/18/23 Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51 04/17/23 Notable companies reporting before tomorrow's open 02/28/23 Fate Therapeutics reports Q4 EPS (58c), consensus (86c) JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/10/23 New suitors showing interest in ShockWave Medical, Street Insider says 05/03/23 Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/02/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/30/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Unusually active option classes on open April 18th 04/06/23 Unusually active option classes on open April 6th 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th
Hot Stocks	Janssen Pharmaceuticals announced results from Phase 1/2 MonumenTAL-1 study » 17:39 06/03/23 06/03 17:39 06/03/23 17:39 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) The Janssen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:39 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/03/23 Janssen announces results from Phase 1b RedirecTT-1 study 05/31/23 Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis 05/25/23 Legend: Type II variation application submitted to EMA for CARVYKTI 05/25/23 Bristol-Myers granted FDA Fast Track Designation for 3 milvexian indications JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/30/23 RBC Capital Kenvue initiated with an Outperform at RBC Capital 05/30/23 Citi Johnson & Johnson resumed with a Buy at Citi 05/30/23 JPMorgan JPMorgan starts Kenvue with Overweight on 'resilient growth' 05/30/23 Goldman Sachs Kenvue initiated with a Neutral at Goldman Sachs JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65 04/18/23 Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51 04/17/23 Notable companies reporting before tomorrow's open 02/28/23 Fate Therapeutics reports Q4 EPS (58c), consensus (86c) JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/10/23 New suitors showing interest in ShockWave Medical, Street Insider says 05/03/23 Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/02/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/30/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Unusually active option classes on open April 18th 04/06/23 Unusually active option classes on open April 6th 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th
Hot Stocks	Replimune Group announces 3 trial-in-progress abstracts at ASCO » 17:26 06/03/23 06/03 17:26 06/03/23 17:26 REPL Replimune Group $19.00 / +0.55 (+2.98%) Additional Abstracts… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly REPL Replimune Group $19.00 / +0.55 (+2.98%) 06/03/23 Replimune presents data from Phase 1 trial of RP2 with nivolumab at ASCO 06/03/23 Replimune presents RP1 data from IGNYTE trial at ASCO 05/18/23 Replimune Group enters transition, separation agreement with CFO Jean Franchi 05/18/23 Replimune Group expects cash to fund operations into 2H25 REPL Replimune Group $19.00 / +0.55 (+2.98%) 04/17/23 Piper Sandler Replimune Group assumed with an Overweight at Piper Sandler 02/10/23 H.C. Wainwright Replimune Group price target raised to $50 from $48 at H.C. Wainwright 01/04/23 EF Hutton Replimune Group initiated with a Buy at EF Hutton 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks REPL Replimune Group $19.00 / +0.55 (+2.98%) 05/18/23 Replimune Group reports 2023 EPS ($2.99), consensus ($2.85) 02/09/23 Replimune Group reports Q3 EPS (69c), consensus (75c) 09 Dec REPL Replimune Group $19.00 / +0.55 (+2.98%) 12/09/22 Biotech Alert: Searches spiking for these stocks today
Hot Stocks	Replimune presents data from Phase 1 trial of RP2 with nivolumab at ASCO » 17:26 06/03/23 06/03 17:26 06/03/23 17:26 REPL Replimune Group $19.00 / +0.55 (+2.98%) , BMY Bristol-Myers $65.66 / +0.98 (+1.52%) Replimune Group (REPL)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 06/03/23 Replimune presents RP1 data from IGNYTE trial at ASCO 05/18/23 Replimune Group enters transition, separation agreement with CFO Jean Franchi 05/18/23 Replimune Group expects cash to fund operations into 2H25 01/04/23 Replimune Group announces inducement grants under Nasdaq listing rule BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/30/23 Bristol-Myers' repotrectinib application in lung cancer accepted by FDA 05/26/23 Bristol-Myers reports CHMP opinion recommending approval for Opdivo combination 05/25/23 Bristol-Myers to present first results from Phase 3 COMMANDS study of Reblozyl REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 04/17/23 Piper Sandler Replimune Group assumed with an Overweight at Piper Sandler 02/10/23 H.C. Wainwright Replimune Group price target raised to $50 from $48 at H.C. Wainwright 01/04/23 EF Hutton Replimune Group initiated with a Buy at EF Hutton 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/01/23 Barclays Bristol-Myers price target lowered to $65 from $66 at Barclays 04/28/23 Credit Suisse Bristol-Myers price target lowered to $72 from $78 at Credit Suisse 04/21/23 BofA Bristol-Myers price target raised to $85 from $82 at BofA 04/20/23 H.C. Wainwright Legend Biotech price target raised to $77 from $66 at H.C. Wainwright REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 05/18/23 Replimune Group reports 2023 EPS ($2.99), consensus ($2.85) 02/09/23 Replimune Group reports Q3 EPS (69c), consensus (75c) BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 04/27/23 Bristol-Myers backs FY23 adjusted EPS view $7.95-$8.25, consensus $8.06 04/27/23 Bristol-Myers reports Q1 adjusted EPS $2.05, consensus $1.97 04/26/23 Notable companies reporting before tomorrow's open 09 Dec BMY BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 01/04/23 Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 12/09/22 Biotech Alert: Searches spiking for these stocks today BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers 01/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology 07/27/23 Bristol-Myers - BMY 06/16/23 PDUFA Date for CAMZYOS 12/16/23 PDUFA Date for Abecma BMY BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/10/23 Bristol Myers Squibb put volume heavy and directionally bearish 02/24/23 Bristol Myers Squibb put volume heavy and directionally bearish
Hot Stocks	Replimune presents RP1 data from IGNYTE trial at ASCO » 17:26 06/03/23 06/03 17:26 06/03/23 17:26 REPL Replimune Group $19.00 / +0.55 (+2.98%) , BMY Bristol-Myers $65.66 / +0.98 (+1.52%) Replimune (REPL)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:26 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate Periodicals On The Fly Events Options REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 05/18/23 Replimune Group enters transition, separation agreement with CFO Jean Franchi 05/18/23 Replimune Group expects cash to fund operations into 2H25 01/04/23 Replimune Group announces inducement grants under Nasdaq listing rule 01/04/23 Replimune Group appoints Chris Sarchi as CCO, Sushil Patel as CSO BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/30/23 Bristol-Myers' repotrectinib application in lung cancer accepted by FDA 05/26/23 Bristol-Myers reports CHMP opinion recommending approval for Opdivo combination 05/25/23 Bristol-Myers to present first results from Phase 3 COMMANDS study of Reblozyl 05/25/23 Bristol-Myers says Breyanzi first and only CAR-T to deliver efficacy in CLL/SLL REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 04/17/23 Piper Sandler Replimune Group assumed with an Overweight at Piper Sandler 02/10/23 H.C. Wainwright Replimune Group price target raised to $50 from $48 at H.C. Wainwright 01/04/23 EF Hutton Replimune Group initiated with a Buy at EF Hutton 01/02/23 Barclays Barclays views GSK acquisition interest as positive for oncology stocks BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 05/01/23 Barclays Bristol-Myers price target lowered to $65 from $66 at Barclays 04/28/23 Credit Suisse Bristol-Myers price target lowered to $72 from $78 at Credit Suisse 04/21/23 BofA Bristol-Myers price target raised to $85 from $82 at BofA 04/20/23 H.C. Wainwright Legend Biotech price target raised to $77 from $66 at H.C. Wainwright REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 05/18/23 Replimune Group reports 2023 EPS ($2.99), consensus ($2.85) 02/09/23 Replimune Group reports Q3 EPS (69c), consensus (75c) BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 04/27/23 Bristol-Myers backs FY23 adjusted EPS view $7.95-$8.25, consensus $8.06 04/27/23 Bristol-Myers reports Q1 adjusted EPS $2.05, consensus $1.97 04/26/23 Notable companies reporting before tomorrow's open 09 Dec BMY BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 01/04/23 Aurinia worth 'keeping closer eye on' after settlement, Dealreporter says REPL BMY REPL Replimune Group $19.00 / +0.55 (+2.98%) 12/09/22 Biotech Alert: Searches spiking for these stocks today BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/06/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 02/02/23 Fly Intel: Pre-market Movers 01/17/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology 07/27/23 Bristol-Myers - BMY 06/16/23 PDUFA Date for CAMZYOS 12/16/23 PDUFA Date for Abecma BMY BMY Bristol-Myers $65.66 / +0.98 (+1.52%) 03/10/23 Bristol Myers Squibb put volume heavy and directionally bearish 02/24/23 Bristol Myers Squibb put volume heavy and directionally bearish
Conference/Events	BTIG healthcare analysts to hold a reception » 17:25 06/03/23 06/03 17:25 06/03/23 17:25 Healthcare Analysts hold… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:25 Get Free Trial
Hot Stocks	Janssen announces results from Phase 1b RedirecTT-1 study » 17:18 06/03/23 06/03 17:18 06/03/23 17:18 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) The Janssen… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:18 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/31/23 Janssen says Tremfya showed 'sustainable improvements' in psoriatic arthritis 05/25/23 Legend: Type II variation application submitted to EMA for CARVYKTI 05/25/23 Bristol-Myers granted FDA Fast Track Designation for 3 milvexian indications 05/12/23 Protagonist and Janssen report data from preclinical studies of JNJ-2113 JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/30/23 RBC Capital Kenvue initiated with an Outperform at RBC Capital 05/30/23 Citi Johnson & Johnson resumed with a Buy at Citi 05/30/23 JPMorgan JPMorgan starts Kenvue with Overweight on 'resilient growth' 05/30/23 Goldman Sachs Kenvue initiated with a Neutral at Goldman Sachs JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Johnson & Johnson raises FY23 adjusted EPS to $10.60-$10.70 from $10.45-$10.65 04/18/23 Johnson & Johnson reports Q1 adjusted EPS $2.68, consensus $2.51 04/17/23 Notable companies reporting before tomorrow's open 02/28/23 Fate Therapeutics reports Q4 EPS (58c), consensus (86c) JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 05/26/23 Health authorities to target next COVID shot to new strain, WSJ says 05/23/23 Amgen, J&J settle patent lawsuit over Stelara biosimilar, Reuters reports 05/10/23 New suitors showing interest in ShockWave Medical, Street Insider says 05/03/23 Johnson & Johnson's Kenvue to price at $22 per share, Bloomberg says JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 06/02/23 Buy/Sell: Wall Street's top 10 stock calls this week 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning 05/30/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology JNJ Johnson & Johnson $156.98 / +2.44 (+1.58%) 04/18/23 Unusually active option classes on open April 18th 04/06/23 Unusually active option classes on open April 6th 04/05/23 Early notable gainers among liquid option names on April 5th 04/05/23 Unusually active option classes on open April 5th
Hot Stocks	Evaxion's trial of EVX-01 met its primary endpoints of safety, tolerability » 17:09 06/03/23 06/03 17:09 06/03/23 17:09 EVAX Evaxion Biotech $1.48 / + (+0.00%) Evaxion Biotech presented… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:09 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly EVAX Evaxion Biotech $1.48 / + (+0.00%) 05/25/23 Evaxion Biotech unveils technology to boost effect of DNA and mRNA vaccines 05/25/23 Evaxion Biotech to present Phase 1 data for personalized cancer vaccine 04/18/23 Evaxion Biotech announces promising data for DNA-based cancer immunotherapy 03/28/23 Evaxion announces increased focus on strategy around core AI capabilities EVAX Evaxion Biotech $1.48 / + (+0.00%) 03/31/23 Lake Street Evaxion Biotech price target lowered to $7 from $18 at Lake Street 11/17/22 Oppenheimer Evaxion Biotech price target lowered to $11 from $16 at Oppenheimer 07/18/22 Oppenheimer Evaxion Biotech assumed with an Outperform at Oppenheimer EVAX Evaxion Biotech $1.48 / + (+0.00%) 05/31/23 Evaxion Biotech reports Q1 EPS (24c) vs (25c) last year 04/27/23 Evaxion Biotech reports Q4 EPS (29c) vs (39c) last year EVAX Evaxion Biotech $1.48 / + (+0.00%) 01/03/23 What You Missed On Wall Street This Morning 01/03/23 Fly Intel: Pre-market Movers

Hot Stocks	Gracell presents long-term follow up data from study evaluating GC012F » 17:07 06/03/23 06/03 17:07 06/03/23 17:07 GRCL Gracell $3.05 / +0.09 (+3.04%) Gracell Biotechnologies… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:07 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings GRCL Gracell $3.05 / +0.09 (+3.04%) 05/15/23 Gracell to host KOL webinar on Multiple Myeloma 05/15/23 Gracell begins study of GC012F in Lupus Erythematosus 03/13/23 Gracell sees cash runway to the end of 2024 02/13/23 Gracell: China's NMPA clears IND application for GC012F GRCL Gracell $3.05 / +0.09 (+3.04%) 03/27/23 Wells Fargo Gracell assumed with an Overweight at Wells Fargo 12/08/22 H.C. Wainwright Gracell initiated with a Buy at H.C. Wainwright 09/22/22 Citi Gracell initiated with a Buy at Citi 08/18/22 Wells Fargo Gracell assumed with an Overweight at Wells Fargo GRCL Gracell $3.05 / +0.09 (+3.04%) 05/15/23 Gracell reports Q1 EPS (RMB 0.45) vs (RMB 0.47) last year 03/13/23 Gracell reports Q4 EPS (6c), consensus (13c)
Hot Stocks	Sutro Biopharma announces results from Phase 1 dose-expansion study of luvelta » 17:02 06/03/23 06/03 17:02 06/03/23 17:02 STRO Sutro Biopharma $4.71 / +0.255 (+5.72%) Sutro Biopharma announced… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 17:02 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events STRO Sutro Biopharma $4.71 / +0.255 (+5.72%) 02/28/23 Sutro Biopharma appoints Borgman as Chief Medical Officer 12/20/22 Sutro Biopharma, Vaxcyte in development option grant deal for cell-free extract 12/07/22 Sutro Biopharma pediatric acute myeloid leukemia treatment granted orphan status STRO Sutro Biopharma $4.71 / +0.255 (+5.72%) 04/03/23 JMP Securities Sutro Biopharma price target lowered to $17 from $20 at JMP Securities 03/31/23 H.C. Wainwright Sutro Biopharma price target lowered to $16 from $20 at H.C. Wainwright 03/20/23 Wells Fargo Sutro transferred with Equal Weight from Overweight at Wells Fargo 01/13/23 Truist Sutro Biopharma price target raised to $25 from $21 at Truist STRO Sutro Biopharma $4.71 / +0.255 (+5.72%) 05/15/23 Sutro Biopharma reports Q1 EPS (85c), consensus (81c) 06/08/23 Sutro Biopharma, Inc.
Hot Stocks	Equitrans Midstream's Mountain Valley Pipeline to proceed » 16:58 06/03/23 06/03 16:58 06/03/23 16:58 ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) On June 3, 2023, the… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:58 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Options ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 05/30/23 Equitrans Midstream rises 34.2% 05/30/23 Equitrans Midstream rises 40.4% 05/30/23 Equitrans Midstream rises 44.7% ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 06/01/23 Wolfe Research Equitrans Midstream upgraded to Outperform from Peer Perform at Wolfe Research 05/30/23 RBC Capital Equitrans Midstream upgraded to Outperform from Sector Perform at RBC Capital 04/21/23 Raymond James Equitrans Midstream initiated with a Market Perform at Raymond James 04/10/23 Barclays Equitrans Midstream price target lowered to $6 from $8 at Barclays ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 05/02/23 Equitrans Midstream reports Q1 adjusted EPS 22c, consensus 15c 02/21/23 Equitrans Midstream sees FY23 adjusted EBITDA $1.06B-$1.14B 02/21/23 Equitrans Midstream sees Q1 adjusted EBITDA $270M-$290M 02/21/23 Equitrans Midstream sees Q1 adjusted EBITDA $270M-$290M ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 05/30/23 What You Missed On Wall Street On Tuesday 05/30/23 What You Missed On Wall Street This Morning ETRN Equitrans Midstream $9.08 / +0.24 (+2.71%) 05/30/23 Unusually active option classes on open May 30th 05/26/23 Equitrans Midstream call volume above normal and directionally bullish
Hot Stocks	Cogent Biosciences announces data from ongoing Phase 3 PEAK trial » 16:56 06/03/23 06/03 16:56 06/03/23 16:56 COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) Cogent Biosciences… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:56 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) 05/09/23 Cogent Biosciences expects cash to fund operations into 2025 04/17/23 Cogent Biosciences presents nonclinical data at AACR 03/17/23 Cogent Biosciences treatment of mastocytosis granted orphan status 01/09/23 Cogent Biosciences announces planned milestones for 2023 COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) 04/27/23 Baird Cogent Biosciences initiated with Outperform, $20 target at Baird 04/27/23 Baird Cogent Biosciences initiated with an Outperform at Baird 04/17/23 Wedbush Wedbush remains bullish on Cogent, says APEX Part 2 likely to succeed 03/27/23 H.C. Wainwright Cogent Biosciences assumed with a Buy at H.C. Wainwright COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) 05/09/23 Cogent Biosciences reports Q1 EPS (54c), consensus (57c) 03/14/23 Cogent Biosciences reports Q4 EPS (56c), consensus (52c) 14 Jun COGT Cogent Biosciences $12.97 / +0.245 (+1.93%) 04/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/07/23 Cogent Biosciences Inc
Hot Stocks	Gilead, Arcus announce updated results from interim analysis of ARC-7 study » 16:53 06/03/23 06/03 16:53 06/03/23 16:53 GILD Gilead $77.88 / +1.665 (+2.18%) , RCUS Arcus Biosciences $21.00 / +0.71 (+3.50%) Gilead Science (GILD) and… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 16:53 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events Options RCUS GILD RCUS Arcus Biosciences $21.00 / +0.71 (+3.50%) 05/26/23 Arcus Biosciences rises 25.4% 05/26/23 Arcus Biosciences rises 22.6% 05/26/23 Arcus Biosciences rises 20.6% GILD Gilead $77.88 / +1.665 (+2.18%) 05/26/23 Gilead announces CHMP reccomendation for the use of Veklury 05/17/23 Gilead to present advances across its oncology pipeline at ASCO Annual Meeting 05/15/23 Arcus Biosciences jumps 2% amid expanded inflammation pact with Gilead 05/15/23 Expanded Gilead- Arcus pact may result in up to $1B in payments to Arcus GILD RCUS GILD Gilead $77.88 / +1.665 (+2.18%) 06/02/23 Argus Gilead continues to make regulatory progress, says Argus 05/16/23 BMO Capital Gilead upgraded to Outperform from Market Perform at BMO Capital 04/28/23 Piper Sandler Gilead assumed with an Overweight at Piper Sandler 04/12/23 Morgan Stanley Gilead price target raised to $85 from $81 at Morgan Stanley RCUS Arcus Biosciences $21.00 / +0.71 (+3.50%) 05/31/23 Barclays Barclays reveals two small cap ideas into ASCO conference 05/26/23 Citi Arcus Biosciences price target raised to $41 from $40 at Citi 03/09/23 Citi Arcus Biosciences price target lowered to $40 from $42 at Citi 12/21/22 Citi Arcus Biosciences selloff a buying opportunity, says Citi RCUS GILD RCUS Arcus Biosciences $21.00 / +0.71 (+3.50%) 05/09/23 Arcus Biosciences reports Q1 EPS ($1.09), consensus ($1.16) 02/28/23 Arcus Biosciences reports Q4 EPS (93c), consensus ($1.07) GILD Gilead $77.88 / +1.665 (+2.18%) 05/15/23 Gilead: Arcus deal may reduce Gilead's FY23 GAAP and non-GAAP EPS by 2c 04/27/23 Gilead backs FY23 adjusted EPS view $6.60-$7.00, consensus $6.84 04/27/23 Gilead reports Q1 Biktarvy sales up 24% y/y 04/27/23 Gilead Sciences reports Q1 adjusted EPS $1.37, consensus $1.54 RCUS GILD RCUS Arcus Biosciences $21.00 / +0.71 (+3.50%) 12/20/22 What You Missed On Wall Street On Tuesday 12/20/22 What You Missed On Wall Street This Morning 12/19/22 Fly Intel: After-Hours Movers GILD Gilead $77.88 / +1.665 (+2.18%) 05/16/23 What You Missed On Wall Street On Tuesday 05/16/23 What You Missed On Wall Street This Morning 05/16/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 04/28/23 Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations 06/09/23 Biotechnology 06/15/23 Arcus Biosciences, Inc. GILD GILD Gilead $77.88 / +1.665 (+2.18%) 05/25/23 Gilead call volume above normal and directionally bullish 05/03/23 Gilead call volume above normal and directionally bullish 04/27/23 Gilead options imply 3.8% move in share price post-earnings 02/03/23 Early notable gainers among liquid option names on February 3rd
Conference/Events	Alamo Group participates in a conference call with DA Davidson » 14:27 06/03/23 06/03 14:27 06/03/23 14:27 ALG Alamo Group $178.29 / +11.4 (+6.83%) Analyst Shlisky holds a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 14:27 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ALG Alamo Group $178.29 / +11.4 (+6.83%) 01/03/23 Alamo Group increases regular dividend 4c to 22c per share ALG Alamo Group $178.29 / +11.4 (+6.83%) 03/16/23 DA Davidson Alamo Group upgraded to Buy from Neutral at DA Davidson 02/27/23 DA Davidson Alamo Group price target raised to $173 from $156 at DA Davidson 11/07/22 DA Davidson Alamo Group price target raised to $156 from $136 at DA Davidson 10/19/22 EF Hutton Alamo Group initiated with a Buy at EF Hutton ALG Alamo Group $178.29 / +11.4 (+6.83%) 05/04/23 Alamo Group reports Q1 EPS $2.79, consensus $2.11 02/23/23 Alamo Group reports Q4 EPS $2.44, consensus $1.99 06/07/23 Alamo Group
Conference/Events	Alamo Group management to meet virtually with DA Davidson » 14:04 06/03/23 06/03 14:04 06/03/23 14:04 ALG Alamo Group $178.29 / +11.4 (+6.83%) Analyst Shlisky holds a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 14:04 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events ALG Alamo Group $178.29 / +11.4 (+6.83%) 01/03/23 Alamo Group increases regular dividend 4c to 22c per share ALG Alamo Group $178.29 / +11.4 (+6.83%) 03/16/23 DA Davidson Alamo Group upgraded to Buy from Neutral at DA Davidson 02/27/23 DA Davidson Alamo Group price target raised to $173 from $156 at DA Davidson 11/07/22 DA Davidson Alamo Group price target raised to $156 from $136 at DA Davidson 10/19/22 EF Hutton Alamo Group initiated with a Buy at EF Hutton ALG Alamo Group $178.29 / +11.4 (+6.83%) 05/04/23 Alamo Group reports Q1 EPS $2.79, consensus $2.11 02/23/23 Alamo Group reports Q4 EPS $2.44, consensus $1.99 06/07/23 Alamo Group
Conference/Events	Peoples Bancorp management to meet virtually with DA Davidson » 13:59 06/03/23 06/03 13:59 06/03/23 13:59 PEBO Peoples Bancorp $27.74 / +1.72 (+6.61%) Analyst Navas holds a… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 13:59 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Events PEBO Peoples Bancorp $27.74 / +1.72 (+6.61%) 04/25/23 Peoples Bancorp raises dividend to 39c 04/14/23 Peoples Bancorp receives regulatory approvals for Limestone Bancorp merger PEBO Peoples Bancorp $27.74 / +1.72 (+6.61%) 04/13/23 Janney Montgomery Scott Peoples Bancorp initiated with a Neutral at Janney Montgomery Scott 02/27/23 Raymond James Limestone Bancorp downgraded to Market Perform from Outperform at Raymond James 10/26/22 Hovde Group Peoples Bancorp downgraded to Market Perform from Outperform at Hovde Group 08/03/22 B. Riley Peoples Bancorp price target raised to $32 from $28 at B. Riley PEBO Peoples Bancorp $27.74 / +1.72 (+6.61%) 04/25/23 Peoples Bancorp reports Q1 EPS 92c, consensus 91c 01/24/23 Peoples Bancorp reports Q4 EPS 92c, consensus 92c 06/07/23 Peoples Bancorp
Hot Stocks	NewAmsterdam's ROSE2 trial on obicetrapib met primary, secondary endpoints » 13:14 06/03/23 06/03 13:14 06/03/23 13:14 NAMS NewAmsterdam $13.78 / +0.025 (+0.18%) NewAmsterdam Pharma… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 13:14 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings NAMS NewAmsterdam $13.78 / +0.025 (+0.18%) 05/08/23 NewAmsterdam announces upcoming milestones 05/08/23 NewAmsterdam expects cash to fund operations through 2026 04/24/23 NewAmsterdam completes enrollment in Phase 3 BROOKLYN TRIAL 04/03/23 NewAmsterdam appoints Janneke van der Kamp to board of directors NAMS NewAmsterdam $13.78 / +0.025 (+0.18%) 01/06/23 Credit Suisse NewAmsterdam initiated with an Outperform at Credit Suisse 12/20/22 SVB Securities NewAmsterdam initiated with an Outperform at SVB Securities 12/19/22 William Blair William Blair starts NewAmsterdam at Outperform on obicetrapib confidence 12/19/22 William Blair NewAmsterdam initiated with an Outperform at William Blair NAMS NewAmsterdam $13.78 / +0.025 (+0.18%) 03/31/23 NewAmsterdam reports 2022 EPS (EUR 0.96) vs. (EUR 1.19) last year
Hot Stocks	Precigen announces Phase 1 data of OTS PRGN-2009 AdenoVerse » 13:09 06/03/23 06/03 13:09 06/03/23 13:09 PGEN Precigen $1.30 / + (+0.00%) Precigen presented… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 13:09 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Syndicate On The Fly Events Options PGEN Precigen $1.30 / + (+0.00%) 05/31/23 Precigen: FDA clears IND to initiate Phase 2 study of PRGN-2009 04/17/23 Precigen's UltraCAR-T platform shows antitumor eefficacy in preclinical data 04/03/23 Precigen amends exclusive license agreement with Alaunos Therapeutics 03/29/23 Precigen: First patient dosed in Phase 1/1b study of of PRGN-3007 PGEN Precigen $1.30 / + (+0.00%) 05/23/23 JPMorgan Precigen initiated with a Neutral at JPMorgan 01/30/23 Cantor Fitzgerald Precigen price target raised to $10 from $7 at Cantor Fitzgerald 12/28/22 Cantor Fitzgerald Cantor calls Merck top large cap pharma pick, names 8 SMID cap top picks 11/18/22 Cantor Fitzgerald Precigen initiated with an Overweight at Cantor Fitzgerald PGEN Precigen $1.30 / + (+0.00%) 05/10/23 Precigen reports Q1 ContOps EPS (10c), consensus (9c) 03/06/23 Precigen reports Q4 EPS (11c), consensus (10c) 25 Jan PGEN Precigen $1.30 / + (+0.00%) 01/27/23 Biotech Alert: Searches spiking for these stocks today 01/25/23 What You Missed On Wall Street On Wednesday 01/25/23 What You Missed On Wall Street This Morning 01/25/23 Fly Intel: Pre-market Movers 06/08/23 Precigen Inc PGEN Precigen $1.30 / + (+0.00%) 03/06/23 Precigen options imply 35.3% move in share price post-earnings 02/08/23 Largest borrow rate increases among liquid names

Hot Stocks	Elevation Oncology, CSPC announces initial clinical data for SYSA1801 » 13:02 06/03/23 06/03 13:02 06/03/23 13:02 ELEV Elevation Oncology $3.54 / -0.46 (-11.50%) , CSPCY CSPC $3.43 / +0.02 (+0.59%) Elevation Oncology (ELEV)… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 13:02 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings ELEV ELEV Elevation Oncology $3.54 / -0.46 (-11.50%) 04/17/23 Elevation Oncology presents EO-3021 preclinical PoC data 01/06/23 Elevation Oncology realigns resources, CEO resigns, cuts workforce by 30% ELEV CSPCY ELEV Elevation Oncology $3.54 / -0.46 (-11.50%) 05/30/23 SVB Securities SVB upgrades Elevation Oncology to Outperform on Claudin18.2 ADC SYSA180 data 05/30/23 SVB Securities Elevation Oncology upgraded to Outperform from Market Perform at SVB Securities 11/10/22 JPMorgan Elevation downgraded to Underweight on more difficult path at JPMorgan 11/10/22 JPMorgan Elevation Oncology downgraded to Underweight from Neutral at JPMorgan CSPCY CSPC $3.43 / +0.02 (+0.59%) 08/02/22 Deutsche Bank CSPC initiated with a Buy at Deutsche Bank ELEV ELEV Elevation Oncology $3.54 / -0.46 (-11.50%) 05/15/23 Elevation Oncology reports Q1 EPS (72c), consensus (59c) 03/09/23 Elevation Oncology reports Q4 EPS (82c0, consensus (78c)
Hot Stocks	Blueprint Medicines announces data from its VELA trial of BLU-222 » 12:59 06/03/23 06/03 12:59 06/03/23 12:59 BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) Blueprint Medicines… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 12:59 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) 06/03/23 Blueprint Medicines announces results from its EGFR Programs 05/23/23 Blueprint Medicines announces publication of results from PIONEER Trial 05/22/23 Blueprint Medicines announces FDA approval of AYVAKIT from treatment of SM 05/22/23 Blueprint Medicines' Ayvakit gets expanded approval for ISM BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) 05/23/23 Guggenheim Blueprint Medicines price target raised to $82 from $78 at Guggenheim 05/23/23 H.C. Wainwright Blueprint Medicines price target raised to $85 from $75 at H.C. Wainwright 05/23/23 Barclays Blueprint Medicines price target raised to $46 from $44 at Barclays 05/05/23 H.C. Wainwright Blueprint Medicines price target raised to $75 from $70 at H.C. Wainwright BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) 05/04/23 Blueprint Medicines reports Q1 EPS ($2.15), consensus ($2.67) 02/16/23 Blueprint Medicines reports Q4 EPS ($2.65), consensus ($2.65) BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) 05/25/23 Biotech Alert: Searches spiking for these stocks today 05/22/23 Fly Intel: After-Hours Movers 03/28/23 Fly Intel: After-Hours Movers 06/21/23 Blueprint Medicines Corp.
Hot Stocks	Blueprint Medicines announces results from its EGFR Programs » 12:59 06/03/23 06/03 12:59 06/03/23 12:59 BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) Blueprint Medicines… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 12:59 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) 05/23/23 Blueprint Medicines announces publication of results from PIONEER Trial 05/22/23 Blueprint Medicines announces FDA approval of AYVAKIT from treatment of SM 05/22/23 Blueprint Medicines' Ayvakit gets expanded approval for ISM 04/26/23 Blueprint Medicines to present new clinical data at 2023 ASCO meeting BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) 05/23/23 Guggenheim Blueprint Medicines price target raised to $82 from $78 at Guggenheim 05/23/23 H.C. Wainwright Blueprint Medicines price target raised to $85 from $75 at H.C. Wainwright 05/23/23 Barclays Blueprint Medicines price target raised to $46 from $44 at Barclays 05/05/23 H.C. Wainwright Blueprint Medicines price target raised to $75 from $70 at H.C. Wainwright BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) 05/04/23 Blueprint Medicines reports Q1 EPS ($2.15), consensus ($2.67) 02/16/23 Blueprint Medicines reports Q4 EPS ($2.65), consensus ($2.65) BPMC Blueprint Medicines $58.22 / +1.39 (+2.45%) 05/25/23 Biotech Alert: Searches spiking for these stocks today 05/22/23 Fly Intel: After-Hours Movers 03/28/23 Fly Intel: After-Hours Movers 06/21/23 Blueprint Medicines Corp.
Hot Stocks	Merck announces results from Phase 3 KEYNOTE-671 trial evaluating KEYTRUDA » 12:50 06/03/23 06/03 12:50 06/03/23 12:50 MRK Merck $112.52 / +1.56 (+1.41%) Merck, known as MSD… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 12:50 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings Periodicals On The Fly Events Options MRK Merck $112.52 / +1.56 (+1.41%) 06/03/23 Merck, CCTG announce results from Phase 3 trial evaluating KEYTRUDA 06/03/23 AstraZeneca interim analysis of DUO-O trial shows statistically significant PFS 06/01/23 AstraZeneca, Merck announce LYNPARZA + abiraterone approved for BRCAm cancer 06/01/23 Merck and AstraZeneca's Lynparza prostate cancer combination approved by FDA MRK Merck $112.52 / +1.56 (+1.41%) 05/10/23 Jefferies Prometheus downgraded to Hold from Buy at Jefferies 05/01/23 Barclays Merck price target raised to $130 from $128 at Barclays 04/18/23 Wells Fargo Prometheus downgraded to Equal Weight from Overweight at Wells Fargo 04/18/23 RBC Capital Prometheus downgraded to Sector Perform from Outperform at RBC Capital MRK Merck $112.52 / +1.56 (+1.41%) 04/27/23 Merck narrows FY23 revenue view to $57.7B-$58.9B from $57.2B-$58.7B 04/27/23 Merck reports Q1 adjusted EPS $1.40, consensus $1.32 04/26/23 Notable companies reporting before tomorrow's open MRK Merck $112.52 / +1.56 (+1.41%) 02/27/23 Pfizer in talks to buy Seagen in deal that may be valued at over $30B, WSJ says 01/13/23 Johnson & Johnson cuts production of Covid-19 vaccine, WSJ reports 01/11/23 Merck, Pfizer rebuff China's efforts to cut Covid drug prices, Bloomberg says 12/30/22 Merck's Covid treatment gets conditional approval in China, Reuters reports MRK Merck $112.52 / +1.56 (+1.41%) 05/16/23 What You Missed On Wall Street On Tuesday 04/27/23 Fly Intel: Pre-market Movers 04/19/23 Biotech Alert: Searches spiking for these stocks today 04/17/23 What You Missed On Wall Street On Monday 08/01/23 Merck - MRK MRK Merck $112.52 / +1.56 (+1.41%) 04/25/23 Merck call volume above normal and directionally bullish 04/17/23 Unusually active option classes on open April 17th 03/10/23 Early notable gainers among liquid option names on March 10th 01/10/23 Largest borrow rate increases among liquid names
Hot Stocks	Allogene Therapeutics presents updated ALLO-501/501A Phase 1 data » 12:45 06/03/23 06/03 12:45 06/03/23 12:45 ALLO Allogene Therapeutics $5.60 / +0.28 (+5.26%) Allogene Therapeutics… Story temporarily locked. To read stories as they happen please subscribe, Login above, or return on Jun 6th, 12:45 Get Free Trial ShowHide Related Items >><< Company News Street Research Earnings On The Fly Events ALLO Allogene Therapeutics $5.60 / +0.28 (+5.26%) 05/11/23 Allogene announces 'encore presentation' of Phase 1 data at EHA congress 05/03/23 Allogene Therapeutics sees decrease in cash/equivalents of $230M in FY23 04/26/23 Allogene to present Phase 1 Data from ALLO-501/501A trials at ASCO 04/20/23 Allogene Therapeutics appoints Timothy Moore as chief technical officer ALLO Allogene Therapeutics $5.60 / +0.28 (+5.26%) 05/05/23 JMP Securities Allogene Therapeutics price target lowered to $15 from $19 at JMP Securities 05/04/23 Stifel Allogene Therapeutics price target lowered to $7.50 from $8.00 at Stifel 04/04/23 H.C. Wainwright Allogene Therapeutics price target lowered to $23 from $29 at H.C. Wainwright 03/21/23 Bernstein Allogene Therapeutics initiated with a Market Perform at Bernstein ALLO Allogene Therapeutics $5.60 / +0.28 (+5.26%) 05/03/23 Allogene Therapeutics reports Q1 EPS,(68c) consensus (62c) 02/28/23 Allogene Therapeutics reports Q4 EPS (66c), consensus (54c) ALLO Allogene Therapeutics $5.60 / +0.28 (+5.26%) 05/04/23 What You Missed On Wall Street On Thursday 05/04/23 What You Missed On Wall Street This Morning 06/13/23 Allogene Therapeutics, Inc.

Events

Earnings calls, analyst events, roadshows and more

AXP ...
Tomorrow at 00:00

FinTech Virtual Bus Tour Conferences

Virtual Tour
Tomorrow at 00:00

Truist Hosted Company Events at 2023 ASCO Annual Meeting Conferences

Chicago, IL
Tomorrow at 00:00

2023 ASCO Annual Meeting Conferences

Chicago, IL
FSS
Tomorrow at 00:00

Federal Signal Firm Sponsored Meetings

Michigan
ASPN
Tomorrow at 00:00

Aspen Aerogels Firm Sponsored Meetings

Boston, MA
TRVI
Tomorrow at 00:00

Trevi Therapeutics Firm Sponsored Meetings
SLG
Tomorrow at 00:00

SL Green Realty Firm Sponsored Meetings

New York, NY
PUBM
Tomorrow at 00:00

PubMatic Firm Sponsored Meetings

San Francisco, CA
MAS
Tomorrow at 00:00

Masco Firm Sponsored Meetings

Toronto
HFWA
Tomorrow at 00:00

Heritage Financial Firm Sponsored Meetings

Los Angeles, CA

View All Events »

1 of

Syndicate

This week’s upcoming IPOs and secondary offerings

Priced
Not Priced

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	No deals
Fri	No deals

Mon	No deals
Tues	No deals
Wed	No deals
Thurs	SXTP X SXTP 60 Degrees Pharmaceuticals IPO Managers: WallachBeth $4.30-6.30 1.415M Shares
Fri	No deals

View All Syndicate Announcements »

Denbury reports Q1 adjusted EPS $1.69, consensus $1.53

OTHER BREAKING NEWS FROM THE FLY

Get Full Fly Access